ClinicalTrialsFinder

FGFR2 Gene Short Variants Clinical Trials in Cleveland, Ohio

1 recruitingCleveland, Ohio

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316